Iron Infusions Narrowly Miss the Mark for Clinical Benefit in Heart Failure

(MedPage Today) -- AMSTERDAM -- Ferric carboxymaltose (FCM) did not go so far as to improve hard outcomes in people with heart failure with reduced ejection fraction (HFrEF) and iron deficiency in the well-powered HEART-FID trial, and it is questionable...
Source: MedPage Today Nephrology - Category: Urology & Nephrology Source Type: news